$PBLS News
Last published 13h ago
- 13h agoPBLSParabilis Medicines, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 13h agoPBLSParabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswirePresented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate at the 32-week landmark and a favorable safety and tolerability profile for zolucatetide in desmoid tumors
- 1w agoPBLSParabilis Medicines to Participate in Upcoming November Investor ConferencesGlobeNewswireCAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (NASDAQ:PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by
- 2w agoPBLSParabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid TumorsGlobeNewswireObjective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmarkDisease control rate of 100% across all response-evaluable patients receiving a starting dose of
- 3w agoPBLSParabilis Medicines to Present Updated Clinical Data for Zolucatetide in Patients with Desmoid Tumors at ESMO Congress 2026GlobeNewswireOral presentation will include updated data from the ongoing Phase 1/2 trial, with dose optimization arm designed to inform dose and regimen selection for Phase 3 registrational trial in desmoid tumors Company to host
- 4w agoPBLSParabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous PolyposisGlobeNewswireNew dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors Zolucatetide directly inhibits β-catenin:TCF, targeting the
- 2mo agoPBLSParabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireCAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (NASDAQ:PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by
- 2mo agoPBLSParabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (NASDAQ:PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by
- 3mo agoPBLSParabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireAdvanced zolucatetide across multiple Wnt/β-catenin-driven diseases, including progress toward planned Phase 3 registrational trial in desmoid tumors Announced strategic research collaboration with Regeneron to
- 5mo agoPBLSParabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional SharesGlobeNewswireCAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (NASDAQ:PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the
- 5mo agoPBLSParabilis Medicines Announces Pricing of Upsized Initial Public OfferingGlobeNewswireCAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (NASDAQ:PBLS) ("Parabilis"), a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the